Unique ID issued by UMIN | UMIN000017179 |
---|---|
Receipt number | R000019935 |
Scientific Title | Examination of the usefulness for the treatment of ulcerative colitis through the change of enterobacterial flora derived by adacolumn treatment. |
Date of disclosure of the study information | 2015/06/01 |
Last modified on | 2018/07/15 02:03:31 |
Examination of the usefulness for the treatment of ulcerative colitis through the change of enterobacterial flora derived by adacolumn treatment.
The usefulness through enterobacterial flora by adacolumn treatment.
Examination of the usefulness for the treatment of ulcerative colitis through the change of enterobacterial flora derived by adacolumn treatment.
The usefulness through enterobacterial flora by adacolumn treatment.
Japan |
ulcerative colitis
Gastroenterology |
Others
YES
To investigate the usefulness of adacolumn (referred to GMA) for the treatment of ulcerative colitis (UC) in view of the change of enterobacterial flora before and after GMA therapy.
Efficacy
The relationship between the change of enterobacterial flora and improvement of endoscopic finding, clinical symptoms.
The change of inflammatory related gene expression in colonic mucosa after GMA treatment.
Interventional
Single arm
Non-randomized
Open -no one is blinded
Uncontrolled
1
Treatment
Device,equipment |
granulocyte and monocyte apheresis (GMA), twice per week, 5 weeks continuously, total 10 times.
20 | years-old | <= |
65 | years-old | >= |
Male and Female
Over 4 points of Lichtiger index score and endoscopic Mayo score 2 and 3.
A kind of the previous treatment and the concomitant drug do not matter
The patient who judged that GMA treatment was appropriate along guidelines on Ministry of Health, Labour and Welfare
a) The re-registration patients for this study
b) The number of granulocyte is under 2,000/mm3
c) A patient complicated with a serious infectious disease
d) Patient with a serious heart trouble
e) Patient with a serious renal trouble
f) Patient with low blood pressure (maximum pressure is under 80mmHg)
g) Patient with pregnancy
h) Strength sthenia pro-extreme dehydration, solidification, patient of serious anemia (less than 8.0 g/dL of hemoglobin)
i) Patient with malignant tumor
j) Patient with stoma
k) Patient who had surgery for intestine with 12 weeks
l) Patient with serious complications out of intestinal tract
m) Patient who had GMA treatment within 4 weeks
n) Patient who had started or increased thiopurine within 8 weeks
o) The patient who judged an arrangement to the final examination if the medical attendant was inappropriate
100
1st name | |
Middle name | |
Last name | Yuji Naito |
Kyoto Prefectural University of Medicine
Department of Molecular Gastroenterology and Hepatology
465 Kajiicho Hirokoji Kawaramachidori Kamigyo-ku Kyoto, Japan
075-251-5519
ynaito@koto.kpu-m.ac.jp
1st name | |
Middle name | |
Last name | Kazuhiko Uchiyama |
Kyoto Prefectural University of Medicine
Department of Molecular Gastroenterology and Hepatology
465 Kajiicho Hirokoji Kawaramachidori Kamigyo-ku Kyoto, Japan
075-251-5519
k-uchi@koto.kpu-m.ac.jp
Kyoto Prefectural University of Medicine, Department of Molecular Gastroenterology and Hepatology
Takeda Pharmaceutical Company Limited
Profit organization
NO
2015 | Year | 06 | Month | 01 | Day |
Unpublished
Open public recruiting
2015 | Year | 06 | Month | 01 | Day |
2015 | Year | 06 | Month | 01 | Day |
2015 | Year | 04 | Month | 20 | Day |
2018 | Year | 07 | Month | 15 | Day |
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000019935